John P. Hamill
2017 - Cellectar Biosciences
In 2017, John P. Hamill earned a total compensation of $169.8K as Interim Chief Financial Officer at Cellectar Biosciences.
Compensation breakdown
| Other | $169,838 |
|---|---|
| Total | $169,838 |
Hamill received $169.8K in other compensation, accounting for 100% of the total pay in 2017.
Rankings
In 2017, John P. Hamill's compensation ranked 14,206th out of 14,666 executives tracked by ExecPay. In other words, Hamill earned more than 3.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 14,206 out of 14,666 | 3rd |
Division Manufacturing | 5,583 out of 5,768 | 3rd |
Major group Chemicals And Allied Products | 2,006 out of 2,074 | 3rd |
Industry group Drugs | 1,668 out of 1,730 | 4th |
Industry Pharmaceutical Preparations | 1,277 out of 1,329 | 4th |
Source: SEC filing on April 23, 2018.
Hamill's colleagues
We found four more compensation records of executives who worked with John P. Hamill at Cellectar Biosciences in 2017.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Discovery Laboratories CEO Craig Fraser's 2022 pay falls 50% to $941K
June 29, 2023
Discovery Laboratories CEO Craig Fraser's 2021 pay jumps 144% to $1.9M
May 11, 2022
Discovery Laboratories COO Eric Curtis receives $1.8M in 2020
April 30, 2021
Cellectar Biosciences CEO James Caruso's 2018 pay falls 23% to $770K
April 29, 2019